Current standard treatment regimens in pancreatic cancer are minimally effective in prolonging overall survival, highlighting the need for novel treatment strategies. The precise function of COXͲ2 in the tumor microenvironment remains incompletely understood but it has been implicated in tumor angiogenesis and epithelial to mesenchymal transition. Apricoxib is a novel COXͲ2 inhibitor in Phase II clinical trials in pancreatic cancer being investigated as a strategy to augment the efficacy of gemcitabine and erlotinib. Here, in preclinical models of pancreatic cancer, apricoxib significantly enhanced the efficacy of gemcitabine plus erlotinib in reducing primary tumor burden and the occurrence of metastases in orthotopic tumor models with elevated COXͲ2 activity. Strikingly, apricoxib treatment also robustly prevented tumor cells from adopting a mesenchymal phenotype in vivo, regardless of COXͲ2 expression levels by the primary tumor. Enhancing an epithelial phenotype via COXͲ2 inhibition may improve efficacy of chemotherapy. Conclusions: Apricoxib robustly reverses EMT and augments standard therapy without reducing microvessel density and warrants further clinical evaluation in patients with pancreatic cancer.
Introduction
The progression of several human cancers, including pancreatic, has been linked to inflammation, which can trigger secretion of growth factors, infiltration of immune cells, and DNA damage by reactive oxygen species leading to tumor cell proliferation and escape from cell death (1) . Epidemiologically, chronic use of antiͲ inflammatory drugs correlates with a reduction in the incidence of certain cancers, including pancreatic cancer (2, 3) . Upregulation of cyclooxygenaseͲ2 (COXͲ2), the rate limiting step in the synthesis of prostaglandins from arachidonic acid, is an early inflammatory response and is regulated by several growth factors and cytokines (4) . Elevated COXͲ2 expression is frequent in many cancers, including pancreatic cancer where it is expressed highly in up to 75% of cases (5) . Increased COXͲ2 in pancreatic tumors correlates with increased invasiveness and shorter overall survival (6Ͳ10). The most abundant product of COXͲ2 in tumors, prostaglandin E 2 (PGE 2 ), can affect multiple carcinogenic pathways and participate in proliferation, invasion, angiogenesis, chemoresistance and metastasis (5, 11Ͳ14). In the pancreas under normal conditions, only islet cells express COXͲ2 (10) . As pancreatic intraepithelial lesions develop, COXͲ2 expression is elevated and the use of COXͲ2 inhibitors can delay the progression of the disease in preclinical KRasͲdriven mouse models. Indeed, inhibition of COXͲ2 can reduce tumor growth in several experimental models of pancreatic cancer (15, 16) . Importantly, prostaglandins secreted from stromal fibroblasts facilitate tumor cell proliferation and survival even in tumors and cell lines where COXͲ2 is not expressed by tumor cells, suggesting that COXͲ2 is an important signaling molecule in the tumor microenvironment (17) . Collectively, these findings make COXͲ2 an attractive target for antiͲcancer therapy.
Despite advances in diagnostics and treatment, the prognosis for inoperable pancreatic cancer remains poor, largely due to local invasion and metastatic progression at early stages (18) . The current standard of care for pancreatic cancer is gemcitabine but it affords minimal survival benefit to patients (19) . Addition of the COXͲ2 inhibitor celecoxib to gemcitabineͲcontaining regimens have yielded mixed results; indeed, strategies Author Manuscript Published OnlineFirst on July 24, 2012; DOI: 10.1158/1078-0432.CCR- to augment gemcitabine activity have largely failed to improve overall survival in Phase III clinical studies, excepting combination with erlotinib, an inhibitor of epidermal growth factor receptor (EGFR). However, while statistically significant, erlotinibͲbased improvement remains modest (20, 21) . Rationale exists for the combined targeting of EGFR and COXͲ2 as significant overlap and interaction occur between these pathways. PGE 2 can transactivate EGFR, which can subsequently increase expression of COXͲ2. In addition, PGE 2 , via promotion of epithelial to mesenchymal transition (EMT), can increase resistance to EGFR inhibitors (22) .
Furthermore, shortͲcircuiting both pathways simultaneously can have synergistic effects in preclinical cancer models (23Ͳ25).
The mechanistic basis of COXͲ2 inhibitor therapy in pancreatic cancer remains illͲdefined, although in the HT29 model of colorectal cancer reversion of the EMT phenotype has been reported to be a key mechanism of action (26). Apricoxib is a novel, selective COXͲ2 inhibitor currently in Phase II studies for NSCLC and pancreatic cancer. Apricoxib has demonstrated significant antitumor effects in xenograft models of lung and colorectal cancer and appears more potent than previous COXͲ2 inhibitors (23, 27, 28) . In the present study, we characterized the baseline expression and activity of EGFR and COXͲ2 in commonlyͲemployed pancreatic cancer cell lines as well as functional responses to inhibition of each pathway. In vivo studies with COXͲ2 positive and negative cell lines demonstrated that addition of apricoxib enhanced the antiͲtumor efficacy of gemcitabine and erlotinib in COXͲ2Ͳdependent models. We present evidence that apricoxib adds significantly to the treatment effect of standard therapy in COXͲ2 expressing cell lines and also promotes vascular stabilization while reversing EMT regardless of the COXͲ2 status of the primary tumor.
Research. were grown in a humidified atmosphere with 5% CO 2 , at 37qC, and have been DNA fingerprinted for provenance using the PowerPlex 1.2 kit (Promega) and confirmed to be the same as the DNA fingerprint library maintained by ATCC and confirmed to be free of mycoplasma by the eͲMyco kit (Boca Scientific).
Baseline expression status.
For Western blot analysis, cell lysates were produced using MPER (Pierce) with added protease and phosphatase inhibitors (Pierce) and protein concentration was determined by BCA assay (Pierce). Immunodetection was performed by electrophoretic transfer of SDSͲPAGE separated proteins to PVDF membranes. Antibodies used for Western blot analysis included EGFR (Upstate), Tyr 1069 phosphoͲEGFR and CoxͲ2 (Santa Cruz).
For PCR analysis, RNA was prepared using TRIzol (Invitrogen) per manufacturer instructions and concentration was determined by spectrophotometry. The cDNA used for subsequent for PCR was made using iScript (BioͲRad Laboratories) and Choice DNA Taq polymerase (Denville Scientific). The expression of COXͲ2 and EGFR was analyzed by quantitative realͲtime PCR using ɴͲactin as an internal reference gene. Each reaction was performed in triplicate with RNA harvested from 3 independent cell cultures. The comparative Ct method was used to compute relative expression values (29) .
In vitro cytotoxicity and drug response assay. MTS assays were performed in 96Ͳwell plates; cells were plated on day 0 and drug was added on day 1 in fourͲfold dilutions. Drugs were evaluated as single agents with maximum concentration of 2000 nM for gemcitabine and 400 μM for erlotinib and apricoxib. For combination studies gemcitabine was added with a fixed concentration of 1 μM erlotinib, 0.1 μM apricoxib, or 1 μM apricoxib, and triple combination with 1 μM erlotinib and 1 μM apricoxib. Relative cell number was determined by adding MTS (Promega, final concentration 333 ʅg/ml), incubating for 1 to 3 hours at 37°C, and reading absorbance. Drug sensitivity curves and IC 50 s were calculated using inͲhouse software (30) .
PhosphoͲEGFR ELISA (R&D Systems) was performed after incubating cells overnight in a 96Ͳwell plate, serum starving for 4 hours and stimulating for 15 minutes with 10 ng/ml EGF. The plate was processed per manufacturer instructions. PGE 2 ELISA (Cayman) was used to evaluate PGE 2 levels in conditioned media. Cells were plated in 24Ͳwell plates overnight and incubated for 24 hours with increasing concentrations of apricoxib in low serum medium. Assays were performed in triplicate and were performed a minimum of three times.
Animal Studies. All animals were housed in a pathogenͲfree facility with 24Ͳhour access to food and water.
Experiments were approved by, and performed in accordance with, the IACUC at UT Southwestern (Dallas, TX).
4Ͳ6 weeks old female NOD/SCID mice were obtained from a campus supplier. 1x10 6 AsPcͲ1, Colo357, and HPAFͲII cells were injected orthotopically as described (30) Five human pancreatic cancer cell lines were screened for baseline expression of COXͲ2 and EGFR by qPCR. All cell lines expressed detectable levels of mRNA for EGFR and COXͲ2. There was generally close accordance between message and protein, except COXͲ2 levels in AsPCͲ1 cells that were detectable (albeit barely) by qPCR (Fig. 1A ) but not at the protein level (Fig. 1B) . Colo357 cells demonstrated moderate to high expression of COXͲ 2 at the mRNA and protein level (Fig. 1A, B) . PL45, HPAFͲII, and CFPACͲ1 cells exhibited low to moderate expression of COXͲ2 at the mRNA and protein level (Fig. 1A, B) . EGFR expression was detectable in all cell lines by qPCR. The majority of cells displayed low to moderate expression with the exception of AsPCͲ1, which demonstrated relatively high expression (Fig. 1A) . Expression of EGFR at the protein level was assessed by Western blot and confirmed robust expression of EGFR in AsPCͲ1 cells. However, it was notable that phosphorylated EGFR (pͲEGFR) was weak or not detected in the majority of cell lines under basal conditions. In contrast there was a strong pͲEGFR signal in Colo357 cells (Fig. 1B) . The efficacy of erlotinib inhibition of pͲ EGFR after stimulation with EGF in each cell line was determined by ELISA (Fig. 1C ). AsPCͲ1 and HPAFͲII cells were most sensitive with IC 50 s of 0.1 μM and 0.2 μM, respectively. All cells demonstrated an IC 50 below the pharmacologic range (2.2 μM) with the exception of PL45 cells, which were resistant to erlotinib at maximum dose (500 μM, Fig. 1C ). To determine the effect of apricoxib, conditioned media of cells incubated for 24 hours with apricoxib was collected and PGE 2 levels determined. Baseline levels of PGE 2 production by AsPCͲ1 and PL45 cells was minimal at <10 pg/ml (below detectable range) and remained unchanged by apricoxib treatment (AsPCͲ1 shown, Fig. 1D ). Apricoxib effectively prevented PGE 2 production by Colo357 and HPAFͲII cells with IC 50 s within the pharmacologic range (0.5Ͳ2 μM, Colo357, shown in Fig. 1D ). CFPACͲ1 displayed a doseͲdependent reduction but did not achieve an IC 50 within the tested range (max 1 μM, data not shown).
From this we concluded that all cell lines except PL45 demonstrate inhibition of EGFR activity in vitro at
Research. pharmacologically relevant concentrations of drug; however, while most cell lines express COXͲ2, this did not directly correlate to level of PGE 2 production. For cell lines with detectable PGE 2 expression, apricoxib inhibited its production at nanomolar concentrations in vitro.
Erlotinib and apricoxib combination therapy augments efficacy of gemcitabine in vitro.
MTS assays were used to evaluate the antiproliferative effect of each drug as a single agent and in combination. As shown in Table 1 From the in vitro data, we selected a COXͲ2 negative cell line, AsPCͲ1, and two COXͲ2 positive cell lines, one with minimal erlotinib response, Colo357, and a highly erlotinib sensitive line, HPAFͲII for in vivo studies. Mice began therapy 10Ͳ14 days post orthotopic tumor cell injection. Therapy consisted of control (vehicle alone), standard therapy, i.e. 25 mg/kg gemcitabine + 100 μg erlotinib (G+E), or G+E + apricoxib at 10 or 30 mg/kg. AsPCͲ1 and Colo357 tumor bearing mice were sacrificed after 3 weeks of therapy. Tumor and pancreas were dissected en bloc to determine tumor weight. Metastatic burden was initially surveyed by inspection of the abdominal cavity, diaphragm, and liver and later quantified by H&E staining of the left lobe of the liver. For AsPCͲ1 tumors, addition of apricoxib resulted in a significant decrease in primary tumor weight compared to control treated animals (p<0.05, two tailed tͲtest, MannͲWhitney); however, the effect was equivalent to the standard of care, demonstrating that the antitumor activity was due to gemcitabine and erlotinib in this model ( Fig. 2A) . Metastatic burden in AsPCͲ1 bearing mice was highly variable with no significant differences between groups (Fig. 2B) . Mice bearing Colo357 tumors demonstrated a significant reduction in primary tumor size with the standard of care alone compared to saline (p<0.05, ANOVA) and the effect was further enhanced by apricoxib treatment (p<0.05, ANOVA). Metastases in animals bearing Colo357 were virtually eliminated in apricoxib treated groups, with 10 mg/kg showing greatest response (p<0.005 compared to G+E, Dunn MCT, Fig. 2B ). Mice bearing HPAFͲII tumors received therapy for 3 weeks, at which point saline controls were moribund and required sacrifice. HPAFͲII tumors were highly sensitive to erlotinib treatment and at this time all treatment groups had virtually no tumor growth, thus it was elected to sacrifice only 3 animals /group for comparison to control and allow remaining mice to continue on therapy. There were no differences in tumor burden amongst treatment groups at the 3 week time point with all final weights being equivalent to normal pancreas weight. The remaining animals continued on therapy for an additional 4 weeks, at which point apricoxibͲtreated animals showed superior tumor control rate compared to G+E (p<0.001, ANOVA).
Metastases in the HPAFͲII model were suppressed significantly in all treatment groups compared to control animals, but again apricoxib enhanced the activity of G+E, abolishing metastatic spread altogether ( Fig. 2A, B) . (24) is supported by a clear reduction in COXͲ2 expression by G+E treatment, although this value was not statistically significant in either group. Apricoxib treatment virtually eliminated COXͲ2 expression in tumors from both cell lines. PGE 2 is rapidly metabolized in plasma and therefore difficult to assess in vivo.
However, PGE 2 stimulates COXͲ2 expression, forming a positive feedback loop, so reduction in overall COXͲ2 levels demonstrates that apricoxib effectively inhibits PGE 2 production in vivo (32, 33) . In COXͲ2 expressing tumors, this resulted in increased efficacy of standard therapy (Fig 2. A, B) . It has been reported that a COXͲ2 nonͲexpressing cell line can upregulate COXͲ2 under conditions of stress. To recapitulate in vivo changes resulting from tumorͲhost interactions, PGE 2 production was evaluated after forced EMT (26). In Colo357, PGE 2 production was not significantly different between normal and EMT conditions at baseline. At 24 hours following a single dose of apricoxib (0.5 μM), representing the lowest range of in vivo levels (26), PGE 2 levels had decreased by 50% for both conditions. AsPCͲ1 cells, which produce no measurable amount of PGE 2 at baseline, demonstrated a significant increase in PGE 2 levels following induction of EMT. In contrast to Colo357, this was not affected by apricoxib (Fig 2. E) .
Inhibition of COXͲ2 attenuates VEGF and promotes vascular normalization in vivo
Research. 
COXͲ2 expression correlates with VEGF levels in patient tumor samples and COXͲ2 inhibition can modulate VEGF production (27, 34). VEGF levels in plasma and tumor samples collected from mice tumorͲbearing mice were measured by ELISA. In AsPCͲ1 tumorͲbearing mice, plasma VEGF levels were decreased in all treatment groups, but these differences were not significantly different from controlͲtreated animals. In Colo357 tumorͲ bearing mice, VEGF levels were unaffected by G+E treatment but addition of apricoxib resulted in depletion of human VEGF from plasma samples (Fig. 3A) . Interestingly, these changes did not correlate with intratumoral levels of human VEGF. In fact, the lowest levels of tumor associated VEGF were found in G+E treated animals (NS for AsPCͲ1 tumors, p<.005 in Colo357 tumors, Fig. 3B ).
To assess the ultimate effect of COXͲ2 inhibition on angiogenesis, tumor microvessel density was evaluated by immunofluorescence for endomucin and CD31 (CD31 shown, Fig. 3C, D) . Vessel density was decreased moderately by G+E alone (NS for Colo357 but trending downward, p<0.05 for AsPCͲ1); however, addition of apricoxib to the treatment regimen did not significantly alter the effect of G+E on vessel density (Fig. 3C) . To determine if therapy affected pericyteͲendothelial cell interaction, NG2, a pericyte marker, was colocalized with endomucin or CD31 to assess pericyte coverage of vessels. Pericyte coverage index (%NG2 positive vessels) increased significantly in apricoxib treated AsPCͲ1 and Colo357 tumors (p<0.001 AsPCͲ1, <0.05 Colo357, ANOVA, Fig. 3C, D) . In summary, COXͲ2 inhibition did alter plasma levels of VEGF but this did not translate to a change in levels of tumor associated VEGF or neovascularization, instead COXͲ2 inhibition promoted vascular stabilization, which may improve drug delivery as well as contribute to the reduction of metastases (35) .
Inhibition of COXͲ2 reduces proliferation and increases apoptosis.
Inhibition of COXͲ2 activity with apricoxib enhanced the antiͲtumor effect of G+E. To determine if this was due to changes in cell proliferation or survival we evaluated markers of apoptosis and cell proliferation in AsPCͲ1 (Fig. 4A, B) . Apricoxib significantly increased the number of apoptotic cells in AsPCͲ1 and Colo357 tumors. The increase in TUNEL was most evident at the 10 mg/kg dose (Fig. 4A) , but animals treated with 30 mg/kg of apricoxib showed the highest levels of cleaved caspaseͲ3 levels (data not shown). In AsPCͲ1 tumors, proliferative markers (phosphoͲhistone H3 and PCNA) were unchanged (data not shown and Fig. 4C ). By contrast, apricoxib strongly enhanced the modest antiͲproliferative effect of G+E in Colo357 tumors, especially at the 30 mg/kg dose (p<0.01, Fig. 4C, D) . To substantiate the effect of apricoxib on the efficacy of standard therapy we evaluated ɶH2AX levels, which have been shown to mark gemcitabineͲinduced stalled replication forks (36) . yH2AX expression was evaluated by immunofluorescence in Colo357 tumor sections and found to be significantly increased in apricoxib treated tumors compared to either control or G+E treatment alone (p<0.05, Fig. 4E ).
COXͲ2 inhibition reverses EMT
We have recently found that apricoxib reverses EMT in HT29 xenograft (26); thus we assessed tumor sections in the current study for epithelial (EͲcadherin) and mesenchymal (vimentin, and ZebͲ1) markers by immunofluorescence. In Colo357 tumors, vimentin and Zeb1 expression decreased in a doseͲdependent fashion in apricoxibͲtreated animals compared to control and G+E groups, although changes in vimentin expression did not reach statistical significance (p<0.05 vs. control, G+E for Zeb1 Fig. 5A ). Conversely, EͲ cadherin was strongly induced by apricoxib treatment (p<0.001 vs. control, G+E, Fig. 5A ). Representative doubleͲstained images are shown for vimentin and EͲcadherin in Colo357 tumors (Fig. 5B) . Untreated Colo357 tumors demonstrated a mesenchymal phenotype with strong vimentin positive staining and negligible EͲ Cadherin expression. By comparison, Colo357 cells in vitro demonstrate an epithelial phenotype which appears preserved (or reacquired) after apricoxib treatment (Fig. 5C) . Treatment of cells in culture with G+E alone actually increased Zeb1 expression, but combination with apricoxib reversed this effect and dramatically upregulated EͲCadherin expression, (Fig. 5C ). 
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Inhibition of COXͲ2 resulted in a shift toward a more epithelial phenotype regardless of baseline COXͲ2 status of the tumor; although this effect was more dramatic in high COXͲ2 expressing Colo357 tumors and correlated with the overall reduction of metastatic incidence. AsPCͲ1 cells, which increased COXͲ2 expression in vivo and following EMT in vitro (Fig 2E) , demonstrate this shift toward epithelial phenotype by apricoxib treatment with decreased vimentin and Zeb1 and dramatically increased EͲCadherin expression (Fig. 5D) . In vitro, Zeb1 expression by AsPCͲ1 cells is unchanged after G+E or combination with apricoxib. As these cells have undetectable COXͲ2 expression and PGE 2 production under normal culture conditions, EMT was induced in these cells to recapitulate in vivo changes. Following EMT, apricoxib treatment either in combination with G+E or as a single agent at 1 μM significantly diminished Zeb1 expression, this shift did not occur with G+E alone, suggesting that COXͲ2 is intimately involved with the occurrence of EMT and that transformed cells that undergo EMT demonstrate increased sensitivity to apricoxib. 
Discussion
Resistance to chemotherapy remains a major challenge in the treatment of pancreatic cancer, combination strategies to augment gemcitabine failed to demonstrate improved overall survival in phase III clinical trials prior to addition of erlotinib (20) . Early results of small phase II studies combining the COXͲ2 inhibitor celecoxib with gemcitabine or gemcitabine plus irinotecan showed promise with prolonged survival compared to the historic average survival of 6 months for gemcitabine (23) . Apricoxib is currently in Phase II clinical trials in NSCLC and pancreatic cancer. Our studies aimed to determine the antitumor activity of apricoxib in molecularly defined preclinical pancreatic cancer models with the hope of identifying subsets of pancreatic cancer patients who would benefit from the addition of COXͲ2 inhibition to current therapy.
In vitro, we determined the mRNA and protein expression of EGFR and COXͲ2 in cancer cell lines and measured how these targets contribute to cellular response to gemcitabine. We found in all cell lines that concentrations of apricoxib required to exert direct antitumor activity far exceeded those needed to eliminate PGE 2 production (0.5Ͳ2 μM). However, apricoxib at pharmacologically achievable concentrations sensitized cells to standard therapy. This suggests that antitumor effects of COXͲ2 inhibition in these models in vivo resulted primarily from sensitization to gemcitabine/erlotinib therapy or modification of tumorͲhost interactions as opposed to direct antiͲtumor cell effects, although it is possible that COXͲ2Ͳdependent lines would have responded under anchorageͲindependent growth conditions (26). This is also supported by the increased production of PGE 2 in vitro by AsPCͲ1 following forced EMT corresponding to increased COXͲ2 expression by cells in vivo which have adopted an increasingly mesenchymal phenotype.
In vivo, in mice bearing tumors derived from AsPCͲ1, a COXͲ2 lowͲexpressing cell line, addition of apricoxib to standard therapy did not improve antiͲtumor activity nor dramatically effect cell proliferation as measured by PCNA expression. By contrast, in cell lines that express moderate to high levels of COXͲ2 and produce high levels of PGE 2 , significantly increased efficacy was achieved by the addition of apricoxib. These results suggest that clinical studies should consider COXͲ2 activity, not simply expression, when evaluating COXͲ2 and PGE 2 are strongly linked to angiogenesis via promotion of VEGF and bFGF production stimulating growth, migration, and survival of endothelial cells (27, 34) . Reciprocally, these factors form a positive feedback loop amplifying the production of COXͲ2. In our studies, apricoxib did modulate VEGF levels in plasma but this did not result in a reduction in microvessel density. In all tumor groups, VEGF levels were observed to be lowest in tumors that received standard (G+E) therapy. High expression of COXͲ2 corresponds to high VEGF levels in tumor specimens; however, studies have reported that while VEGF production is reduced initially by COXͲ2 inhibition, its production is not exclusively COXͲ2 dependent. Recovery and amplification of VEGF levels may occur as a compensatory response to loss of COXͲ2 activity and levels of VEGF continue to increase with higher doses of COXͲ2 inhibitors (15, 37, 38) . This may provide a plausible explanation for the paradoxical dose response in our models, as well as other preclinical studies. Further these data might also help explain the failure of COXͲ2 inhibitors to demonstrate significant improvement in clinical studies that previously employed doses twice that used for analgesic and antiͲinflammatory effect (39, 40) .
Reciprocally, mechanisms of antiͲVEGF resistance may involve induction of other proͲangiogenic cytokines, such as ILͲ1ɴ and ILͲ8 that are associated with increased COXͲ2 production in the tumor microenvironment.
This collateral pathway may explain why COXͲ2 inhibition alone failed to be significantly antiangiogenic in this model.
Microvessel density was reduced in all therapy groups receiving standard therapy and was unchanged by the addition of apricoxib. The decrease in microvessel density by treatment with gemcitabine has been reported previously (41) and may be a result of the dosing schedule employed. However, apricoxib treatment resulted in increased pericyte coverage of blood vessels. Pericyte attachment is critical for stabilizing vascular structures (35) . Absent or loose pericyte attachment results from imbalanced angiogenic signaling in the tumor leading to dysfunctional vessels that are hallmarked by hyperpermeability. These vessels display abnormal 
blood flow than can increase tumor hypoxia, reduce delivery of chemotherapy and facilitate extravasation and hematogenous spread of metastatic cells (35) . COXͲ2 inhibition impeded this process, suggesting that COXͲ2 participates in vascular remodeling in the tumor microenvironment.
The COXͲ2 product PGE 2 can impact tumor progression and cancer cell proliferation by activating the RasͲMAPK signaling cascade, which subsequently increases expression of PGE 2 synthase, forming a positive feedback loop (42, 43) . Additionally, exogenous PGE 2 can stimulate proliferation of COXͲ2 negative cells in vitro (17) . PGE 2 can mediate cell survival by inducing expression of antiapoptotic proteins such as BclͲ2 and increasing NFʃB transcriptional activity (44). Chemotherapy can increase COXͲ2 protein expression and PGE 2 production, driving tumor cell survival and resistance to therapy. In the present study, proliferative activity in vivo was not affected by COXͲ2 inhibition in AsPCͲ1 tumors; however, apricoxib significantly reduced proliferation in Colo357 tumors. Apoptosis resulting from COXͲ2 inhibition, alternatively, was not specific to COXͲ2 status of the tumor and in each group was most profound in the 10 mg/kg group; indicating that adaptation of AsPCͲ1 cells in vivo can lead to increased dependency on COXͲ2. ɶH2AX has been implicated as a marker of gemcitabine specific DNA damage and was found to be significantly elevated in apricoxib treated tumors. This finding correlated with improvement in apoptotic activity and vessel maturity, indicating that improved chemotherapeutic response may be related in part to improved drug delivery. COXͲ2 and PGE 2 are implicated in driving EMT (45, 46), which contributes to metastasis and resistance to chemotherapy (47, 48). We found that untreated Colo357 and AsPCͲ1 tumors displayed a robust EMT phenotype. In contrast, tumorͲbearing mice that received apricoxib had a noticeable shift to an epithelial phenotype. These observations suggest that COXͲ2 inhibition can reverse EMT in pancreatic tumors. 
Vimentin, a marker of mesenchymal differentiation, is also highly expressed in pancreatic cancers and correlates with poor prognosis (47). Notably, gemcitabine resistance has been linked to vimentin expression in pancreatic cancer cells (50). In vitro, apricoxib dramatically increased EͲCadherin expression in Colo357 cells as well as reversed the increased Zeb1 production observed after G+E treatment. Unsurprisingly, no affect was seen in AsPCͲ1 cells at baseline as they have minimal baseline COXͲ2 activity. However, the increased COXͲ2 production with forced EMT greatly sensitized these cells to apricoxib and demonstrated that apricoxib effectively reversed EMT. This suggests that the maintenance of the mesenchymal phenotype in these cells relies in part on the activity of COXͲ2. In vivo, minimal change was seen in the mesenchymal phenotype of The mean IC 50 (SD) for gemcitabine, erlotinib, and apricoxib was determined by MTS assay as single agents or 
